Weve been looking for a great way to treat this, says Madaio, whose lab developed the antibody that delivered the peptide right to the kidneys
The powder should dissolve completely, leaving you with a clear solution
however, MADRS did not change significantly
Nevertheless, the team did emphasize that the short follow-up period in their study may be insufficient to fully capture the chronic trajectory of glaucoma development, particularly given the recent FDA approval of tirzepatide
And now you are staring at a syringe, a concentration label, and zero confidence about how much to actually inject
ARA-290's FDA Orphan Drug designation specifically addresses sarcoidosis-associated neuropathy, where the clinical evidence is strongest